Cardiol Therapeutics Inc (TSE:CRDL) (OTCQX:CRTPF) CEO David Elsley talks to Proactive about the Oakville, Ontario-based group's clinical studies aimed at treating inflammatory heart disease. Elsley says its recently completed Phase 1 study with CardiolRx supports its Phase II/III COVID-19 trial in patients with prior history of, or risk factors for, cardiovascular disease and the filing of its IND application with the FDA for an international Phase II trial in acute myocarditis.
Cardiol Therapeutics CEO discusses its clinical studies aimed at heart disease and the coronavirus
